U.S. SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported) October 28, 2008

GREATBATCH, INC.
(Exact name of registrant as specified in its charter)

Delaware	1-16137	16-1531026	
(State or other jurisdiction of
incorporation)	(Commission File Number)
 	(IRS Employer Identification No.)

10000 Wehrle Drive, Clarence, New York	14031	
(Address of principal executive offices)	(Zip Code)	

Registrant’s telephone number, including area code  (716) 759-5600

 	Not Applicable		
	(Former name or former address, if changed since last report)		

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
⃞ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
⃞ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
⃞ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
⃞ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.05.      Costs Associated With Exit or Disposal Activities
As part of its continuing efforts to decrease its cost structure and improve manufacturing efficiencies, on October 28, 2008, management of Greatbatch, Inc. (the “Company”) approved a plan for the closure of its Teterboro New Jersey, Blaine Minnesota and Exton Pennsylvania facilities. The operations at these facilities will be moved to existing facilities of the Company with excess capacity.  On October 31, 2008, the Company issued a press release to announce its consolidation plans. A copy of the press release is attached as Exhibit 99.1.
The total cost for these facility consolidations is estimated to be between $5.7 million and $7.0 million. The major categories of costs include the following:
a.  Severance and retention - $2.1 million to $2.5 million;
b.  Production inefficiencies and revalidation - $0.3 million to $0.5 million;
c.  Accelerated depreciation and asset write-offs - $1.5 million to $1.7 million;
d.  Personnel - $1.2 million to $1.4 million; and
e.  Other - $0.6 million to $0.9 million.
All categories of costs are considered to be cash expenditures, except accelerated depreciation and asset write-offs.

 Item 9.01.      Financial Statements and Exhibits
(d) Exhibits
 99.1 Press Release dated October 31, 2008.

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		GREATBATCH, INC.		
		 		
Dated:	October 31, 2008	By:	/s/ Thomas J. Mazza		
			Thomas J. Mazza		
			Senior Vice President and		
			Chief Financial Officer		

EXHIBIT
NUMBER	DESCRIPTION	
	 	
99.1	Press Release of Greatbatch, Inc. dated October 31, 2008.	

Exhibit 99.1
Greatbatch Announces Optimization Plan
CLARENCE, N.Y.--(BUSINESS WIRE)--October 31, 2008--Greatbatch, Inc. today announced a plan to optimize its operating footprint in several locations. “This plan represents the next phase in our strategy to recognize synergies from our recent acquisitions through operational excellence. We remain committed to ongoing improvements in our operating performance through continued facility consolidation, optimizing our production efficiency, and product development activities,” stated Thomas J. Hook President & Chief Executive Officer.
This plan includes the transition of the Company’s Blaine, Minnesota facility to its 98,000 square foot facility in Plymouth, Minnesota. This will involve the transfer of research & development and manufacturing for the catheter and micro-components to the Plymouth facility, where the Company’s leads and introducer operations are currently located. The transfer of employees, products and processes at these locations is anticipated to be completed by the end of the third quarter 2009. “Centralizing our engineering, procurement, regulatory and operations for these product lines in the Minneapolis area will allow us to provide superior customer service, quality and operational excellence,” said Mauricio Arellano, Senior Vice President – Cardiac and Neurology.
In addition, the Commercial business will continue optimizing its facility footprint by transitioning production from its acquired facility located in Teterboro, New Jersey to its newly-constructed Raynham, Massachusetts facility. “The centralization of Commercial battery production in Raynham will allow us to take advantage of our state-of-the-art facilities, providing increased capacity and capabilities of product line operations. The expansion of manufacturing space, dedicated research & development area, and centralized engineering, procurement and operations teams will enable our organization to successfully serve our customers’ expanding needs,” stated Susan Bratton, Senior Vice President - Commercial. The transfer of the Commercial products and processes is targeted to be complete by December 2009.
The third transition relates to the Orthopedics Business and its facility located in Exton, Pennsylvania. Susan Campbell, Senior Vice President - Orthopedics, noted that “Over the next several months, all activities at the Exton facility will be transitioned to other locations with a focus on moving closer to customers, manufacturing sites or our Corporate Technology Center.”
About Greatbatch, Inc.
Greatbatch, Inc. (NYSE: GB) is a leading developer and manufacturer of critical products used in implantable medical devices for the cardiac rhythm management, neuromodulation, vascular and orthopedic markets. Additionally, Electrochem, a subsidiary of Greatbatch, is a world leader in the design and manufacture of technology solutions for some of the world’s most demanding and extreme applications. Additional information about the Company is available at www.greatbatch.com .

CONTACT:
Greatbatch:
Investor Relations:
Marco Benedetti, 716-759-5856
MBenedetti@greatbatch.com